ReviewsPlasma protein binding: From discovery to development
Section snippets
INTRODUCTION TO FREE DRUG THEORY—WHY IS PLASMA PROTEIN BINDING IMPORTANT?
High concentration of proteins in plasma and the propensity of numerous drugs to bind to them have led drug development groups to recognize the importance of plasma protein binding (PPB) in modulating the effective drug concentration at pharmacological target sites. Free drug theory (FDT) is being increasingly used to explain pharmacokinetics/pharmacodynamics (PK/PD) relationships1—FDT states that in absence of energy-dependent processes (uptake and efflux transporters, pH gradient), after
MAJOR DRUG BINDING PROTEINS IN PLASMA
Major drug-binding components in plasma are albumin (human serum albumin—HSA) (600 μM), α-acid glycoprotein (AAG) (12–30 μM), lipoproteins (γ-globulin), and erythrocytes of which drug binding to albumin and AAG has been well studied and extensively published over the past several decades. Although HSA has eight binding sites, capable of binding to endogenous compounds as well as xenobiotics with varying affinities, two major sites of HSA are primarily involved in binding ligands and show a bias
SIMPLE, THEORETICAL CONSIDERATIONS OF PPB
Plasma protein binding is believed to have a significant influence in the rate of drug diffusion between plasma and tissues (influx and efflux)9 and therefore influence clearance (Cl) and volume of distribution (Vdss) of drugs. Effect of PPB on Cl is dependent on major route of Cl of the drug and in case of hepatically cleared drugs, on the liver extraction ratio. For renally extracted drugs, Cl due to glomerular filtration and active secretion are dependent on fu as only unbound drug can be
Endocrinology/Metabolism
Plasma protein binding optimization proved to be very useful in the development of depeptidyl peptidase DPP-IV inhibitors, for the treatment of type 2 diabetes mellitus. First-generation lead compound, although very potent, needed much higher than expected plasma concentration (based on its in vitro potency) for efficacy in preclinical model.11 To understand the disconnect between potency and efficacy, when the in vitro assay was performed with mouse and human serum, compound A (Fig. 4) showed
Nonsteroidal anti-inflammatory drugs
Aspirin, naproxen, piroxicam, ibuprofen, phenylbutazone, indomethacin, flurbiprofen, ketoprofen, methyl salicylate, diflunisal (Fig. 16) are some of the well-known NSAIDS used in the clinic for the treatment of inflammation-related diseases, for example, rheumatoid arthritis and chronic pain. All NSAIDS, with the exception of aspirin, are extremely highly plasma protein bound, which impacts not only their PK properties (Vdss, Cl, and t1/2), but also the duration and magnitude of their efficacy.
Species-Dependent PPB
Although not very common, sometimes, a significant difference in PPB between species is encountered and this can sometimes have major implications in predicting/determining safety and tolerability.ce:list id="l0020">
- •
This is well exemplified in the case of anticancer drug UCN-01 (Fig. 33). UCN-01 demonstrated much unexpected PK (low Vdss, low Cl) in humans that were not predicted from preclinical data (high Vdss and high Cl). This significant difference in PK between humans and preclinical
CLINICALLY RELEVANT PPB–DDI
Clinical relevance of PPB displacement, resulting in a clinically relevant DDI has been an area of much discussion and debate.3,10,61,110., 111., 112., 113., 114., 115., 116., 117. There are several examples in literature where PPB displacement was originally proposed to cause a clinical risk, especially those with warfarin, tolbutamide, and phenytoin (all with NTI), but recent evaluation of these DDIs revealed that inhibition of metabolism of the victim drugs by the corresponding perpetrator
METHODOLOGY
Several different PPB methods have been reported to in literature, a brief summary of which is provided inTable 5.
The “gold standard” methods for PPB are equilibrium dialysis, ultrafiltration and untracentrifugation, with gel filtration method being very popular as well. Readers are encouraged to refer to some excellent reviews.38,127 Some of the major methods are briefly discussed below:
EXCEPTIONS TO FDT
Very simply, this can be described as when unbound drug in a compartment does not correlate to target receptor occupancy within that compartment, leading to a disconnect between unbound drug level and pharmacological activity. This is possible when certain key underlying assumptions of FDT are not met10,61,117:
- (a)
drug has attained steady state between plasma (plasma protein binding) and target tissue (receptor and site of action), but there are certain special cases when SS equilibrium is not
SUMMARY—DISCOVERY RESEARCH TO PRECLINICAL DEVELOPMENT STAGE
There have been extensive publications highlighting PPB optimization in drug discovery. It is widely believed that compounds that show less than 85% bindings are of little concen.95 However, “one glove fits all” theory does not work during lead optimization stage, that is, there is no “optimum/desired/cutoff” value of PPB that will ensure success of a chemical series to be successful. There are some misconceptions surrounding PPB, which are briefly discussed below:
- •
Lowering PPB and optimizing
SUMMARY—CLINICAL DEVELOPMENT STAGE
It is very useful to consider several aspects of PPB in clinical situation, as learnt from the reports sited in literature and some of the important ones are discussed below:
- •
DDI due to PPB displacement. To precipitate a DDI due to PPB displacement between two drugs, both drugs have to be (a) very highly bound and exceed concentration of the plasma protein that is (are) involved in binding of the drugs. For example, HSA concentration is approximately 600 μM, so even if two highly bound drugs
RECOMMENDATIONS (DISCOVERY RESEARCH TO PRECLINICAL DEVELOPMENT STAGE)
In early stages of drug discovery (lead identification/lead optimization stages), significant resources to perform detailed PPB evaluation is not recommended and a simple approach as outlined in Figure 52 is advised to be adopted. Final decision regarding PPB optimization strategy and assay type should be decided by drug discovery projects after thorough evaluation of project requirements, as it must be emphasized that optimum/ideal PPB values can be very different from one chemical series to
RECOMMENDATIONS (CLINICAL DEVELOPMENT STAGE)
Role of PPB on efficacy models needs to be rigorously evaluated and established throughout the preclinical and clinical development stages. Although a general scheme is outlined in Figure 53, it is up to the PK scientists to evaluate the PPB-efficacy relationships to design the best studies addressing this issue on a case-by-case basis. It is crucial to understand the differences (if any) of PPB between healthy (population in which therapeutic concentration range was initially investigated in)
REFERENCES (165)
- et al.
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug–drug interactions from in vitro data
J Pharm Sci
(2006) Influence of race or ethnicity on pharmacokinetics of drugs
J Pharm Sci
(1997)- et al.
Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors
Bioorg Med Chem Lett
(2005) - et al.
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
Bioorg Med Chem Lett
(2006) - et al.
Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin
Eur J Med Chem
(2006) - et al.
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors
Bioorg Med Chem Lett
(2006) - et al.
Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation
Bioorg Med Chem
(2009) - et al.
Current perspective of TACE inhibitors: A review
Bioorg Med Chem
(2009) Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management
Clin Chim Acta
(2007)- et al.
Pharmacokinetic-pharmacodynamic modeling: Time-dependent protein binding—An alternative interpretation of clockwise and counterclockwise hysteresis
J Pharm Sci
(1992)